An observational study in Adult Growth Hormone Deficiency, sponsored by Novo Nordisk A/S. Active, not recruiting at 47 sites in Japan. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Novo Nordisk A/S · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Dwarfism, Pituitary by Novo Nordisk A/S — 2 open to participants now, 3 under way, none of them phase 3. Dwarfism, Pituitary · Novo Nordisk A/S.
Among the 27 studies in Dwarfism, Pituitary by Novo Nordisk A/S, this one is the 8th largest by planned enrollment of the 10 observational ones that give a count, is the only one that started in 2022, is one of 10 observational ones, and was the 25th registered.
252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.
Browse Dwarfism, Pituitary studies →2 of the 27 studies in Dwarfism, Pituitary by Novo Nordisk A/S are open now, in 7 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United Kingdom
Ages up to 18
Novo Nordisk A/S · Sites in United States, France, Germany and 3 more countries
Ages 18+
By country, each count listing its studies:
Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 2022.
This study's planned enrollment of 200 is above the median of 70 across 73 observational studies indexed under Dwarfism, Pituitary.
Median enrollment 86 across the 17 interventional studies, 394 across the 10 observational. Of the 24 that completed or were terminated, 3 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
1 of the studies in Dwarfism, Pituitary by Novo Nordisk A/S that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05230550Novo Nordisk A/SPost-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya® | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies in Dwarfism, Pituitary by Novo Nordisk A/S, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Participants are invited to take part in this study because they have AGHD (only severe case). The purpose of this study is to assess long term safety and effectiveness of Sogroya® in patients with AGHD (only severe case) under normal clinical practice condition in Japan. Participants will get Sogroya® as prescribed by the study doctor. Participants will be in the study for about 2 to 5 years depending on when they take part in the study. Participants will be asked to fill in the quality of life questionnaires.
Patients with Adult Growth Hormone Deficiency (only severe case)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be treated with commercially available Sogroya® according to routine clinical practice at the discretion of the treating physician. The decision to treat a patient with Sogroya® has been made at the treating physician's discretion and independently from the decision to include the patient in this study.
Drug: Somapacitan
Sogroya® therapy in participants with AGHD (only severe case) under normal clinical practice conditions
Also known as: Sogroya®
Number of adverse events
Measured as number
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Number of serious adverse events
Measured as number
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Number of serious adverse reactions
Measured as number
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Number of adverse reactions
Measured as number
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in body fat mass
Measured as kilogram (kg)
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in body fat percentage
Measured as percent (%)
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in lean body mass
Measured as kg
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in cross-sectional total adipose tissue compartments (TAT)
Measured as square centimeter (cm\^2)
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in subcutaneous adipose tissue compartments (SAT)
Measured as cm\^2
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in visceral adipose tissue compartments (VAT)
Measured as cm\^2
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in Total cholesterol (T-Cho)
Measured as milligrams per deciliter (mg/dL)
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in Low Density Lipoprotein-Cholesterol (LDL-Cho)
Measured as mg/dL
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in High Density Lipoprotein-Cholesterol (HDL-Cho)
Measured as mg/dL
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in triglyceride
Measured as mg/dL
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in Insulin-like Growth Factor I (IGF-I) standard deviation score (SDS)
Measured as standard deviation score
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in Quality of Life (QOL) Adult Hypopituitarism Questionnaire (AHQ) score
Measured as score range (0 = unfavorable to 6 = favorable)
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Change in QOL Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD) score
Measured as score range (1 to 5; lower score indicates a better health state)
Time frame: From baseline (week 0) to end of study (up to 260 weeks)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Started Feb 2022 (actual). Primary completion is estimated for Dec 2026, 58 months after the start.
Of 30 observational studies under Dwarfism, Pituitary, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 102. This study's planned 58 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.